A Phase 2 Trial of PT2977, a HIF-2α Inhibitor, in Patients With Von Hippel Lindau disease (VHL).
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs PT 2977 (Primary)
- Indications Von Hippel-Lindau disease
- Focus Therapeutic Use
- 27 Dec 2017 New trial record